Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bright

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Cancer Research|March 1, 1996
Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigenR K Bright, B Beames, M H Shearer, et al.
Journal of Translational Medicine|July 31, 2004
Cancer immunotherapy: avoiding the road to perditionMaurizio Chiriva-Internati, Fabio Grizzi, Robert K Bright, et al.
Angewandte Chemie (International Ed. in English)|July 20, 2016
Reagent-Controlled α-Selective Dehydrative Glycosylation of 2,6-Dideoxy- and 2,3,6-Trideoxy SugarsJason M Nogueira, Marissa Bylsma, Danielle K Bright, et al.
Cancer Gene Therapy|January 5, 2002
Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenograftsK Kawakami, S R Husain, R K Bright, et al.
Ear and Hearing|April 1, 1992
Processing the telephone speech signal for the hearing impairedM Terry, K Bright, M Durian, et al.
Developments in Biological Standardization|October 17, 1998
Immunotherapy of SV40 induced tumours in mice: a model for vaccine developmentR K Bright, M H Shearer, H I Pass, et al.
Cancer Research|April 5, 2005
Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastasesJennifer D Lewis, Michael H Shearer, Ronald C Kennedy, et al.
Oncoimmunology|September 28, 2013
Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigenJennifer D Bright, Heather N Schultz, Jennifer A Byrne, et al.
The Journal of Organic Chemistry|March 11, 2017
Mild Method for 2-Naphthylmethyl Ether Protecting Group Removal Using a Combination of 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and β-PineneDina Lloyd, Marissa Bylsma, Danielle K Bright, et al.
Human Vaccines & Immunotherapeutics|November 27, 2019
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52C Riccay Elizondo, Jennifer D Bright, Jennifer A Byrne, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Cancer Research|March 1, 1996
Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigenR K Bright, B Beames, M H Shearer, et al.
Journal of Translational Medicine|July 31, 2004
Cancer immunotherapy: avoiding the road to perditionMaurizio Chiriva-Internati, Fabio Grizzi, Robert K Bright, et al.
Angewandte Chemie (International Ed. in English)|July 20, 2016
Reagent-Controlled α-Selective Dehydrative Glycosylation of 2,6-Dideoxy- and 2,3,6-Trideoxy SugarsJason M Nogueira, Marissa Bylsma, Danielle K Bright, et al.
Cancer Gene Therapy|January 5, 2002
Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenograftsK Kawakami, S R Husain, R K Bright, et al.
Ear and Hearing|April 1, 1992
Processing the telephone speech signal for the hearing impairedM Terry, K Bright, M Durian, et al.
Developments in Biological Standardization|October 17, 1998
Immunotherapy of SV40 induced tumours in mice: a model for vaccine developmentR K Bright, M H Shearer, H I Pass, et al.
Cancer Research|April 5, 2005
Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastasesJennifer D Lewis, Michael H Shearer, Ronald C Kennedy, et al.
Oncoimmunology|September 28, 2013
Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigenJennifer D Bright, Heather N Schultz, Jennifer A Byrne, et al.
The Journal of Organic Chemistry|March 11, 2017
Mild Method for 2-Naphthylmethyl Ether Protecting Group Removal Using a Combination of 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and β-PineneDina Lloyd, Marissa Bylsma, Danielle K Bright, et al.
Human Vaccines & Immunotherapeutics|November 27, 2019
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52C Riccay Elizondo, Jennifer D Bright, Jennifer A Byrne, et al.
Pageof 11